Modus Therapeutics: Executing on an ambitious timeline - Carlsquare

Modus Therapeutics continues to take important steps in its clinical journey. The first patient was dosed in the important Phase Ib LPS provocation study. We are impressed by the high efficacy of the Company’s activities, as the planned start of the study was set against an ambitious timeline. In our opinion, this is a sign of strength and indicates that the Company will work hard for its owners to keep the plan on track. Data from the study is expected to be presented as early as April 2022 and may first indicate sevuparin’s potential efficacy while generating additional safety data relevant to future patient studies. The news that the study is now underway is an important milestone.

Länk till analysen i sin helhet: https://www.carlsquare.com/mrkt-buzz-modus-exekverar-pa-ambitios-tidslinje/